LONDON (Alliance News) - GlaxoSmithKline PLC on Friday said it has received positive results from the phase 3 study investigating the combination of the dabrafenib and trametinib drugs.
Glaxo said the overall survival rates from the combination of the drugs showed a statistically significant fall in the risk of death from combining the pair in comparison to dabrafenib monotherapy in patients with BRAF V600E/K mutation-positive metastatic melanoma.
No new safety concerns were observed in the test, Glaxo said, and the safety profile was in line with previous studies.
"These final overall survival results from COMBI-d, the second phase III study to show positive survival results for the combination compared to BRAF inhibitor monotherapy, further reinforce the scientific rationale for combining MEK and BRAF inhibitors and underscore the potential of the combination of dabrafenib and trametinib in the treatment of BRAF V600 mutation-positive metastatic melanoma," said Patrick Vallance, the president of pharmaceuticals research and development at Glaxo.
By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.